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Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system, which is
heterogenous with respect to clinical manifestations and response to therapy. Identification of biomarkers appears desirable
for an improved diagnosis of MS as well as for monitoring of disease activity and treatment response. MicroRNAs (miRNAs)
are short non-coding RNAs, which have been shown to have the potential to serve as biomarkers for different human
diseases, most notably cancer. Here, we analyzed the expression profiles of 866 human miRNAs. In detail, we investigated
the miRNA expression in blood cells of 20 patients with relapsing-remitting MS (RRMS) and 19 healthy controls using a
human miRNA microarray and the Geniom Real Time Analyzer (GRTA) platform. We identified 165 miRNAs that were
significantly up- or downregulated in patients with RRMS as compared to healthy controls. The best single miRNA marker,
hsa-miR-145, allowed discriminating MS from controls with a specificity of 89.5%, a sensitivity of 90.0%, and an accuracy of
89.7%. A set of 48 miRNAs that was evaluated by radial basis function kernel support vector machines and 10-fold cross
validation yielded a specificity of 95%, a sensitivity of 97.6%, and an accuracy of 96.3%. While 43 of the 165 miRNAs
deregulated in patients with MS have previously been related to other human diseases, the remaining 122 miRNAs are so far
exclusively associated with MS. The implications of our study are twofold. The miRNA expression profiles in blood cells may
serve as a biomarker for MS, and deregulation of miRNA expression may play a role in the pathogenesis of MS.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
diseaseofthe brainand spinalcord,primarily affectingyoung adults
[1]. It is widely believed that MS is an immune-mediated disease
whose clinical manifestations and course, as well as response to
therapy appear to be heterogeneous, as may be the underlying
pathogenic mechanisms [1]. Biomarkers are defined as parameters
that can be objectively measured and evaluated as indicators of
pathogenic processes or responses to a therapeutic intervention [2].
Identification of reliable biomarkers for MS bears the potential for
an improved diagnosis of MS, monitoring of disease activity and
progression, and evaluation of treatment responses. In recent years,
the field of biomarker discovery has gradually shifted from the aim
of finding a single perfect surrogate marker to the construction of
composite markers with higher performance, taking advantage of
technologies allowing unbiased screening, including microarray
analyses. However, identification of suitable biomarker sets for MS
based on parameters in peripheral blood is only in its infancy [2,3].
MicroRNAs (miRNAs) are short (about 22 nucleotides in
length) single-stranded regulatory RNAs that modulate gene
expression at the posttranscriptional level by repressing translation
of specific messenger RNA (mRNA) targets, eventually resulting in
downregulation of protein expression. They play important roles
in a variety of physiologic and pathologic processes, most notably
oncogenesis [4,5]. Furthermore, miRNAs are involved in the
regulation of the immune system [6]. Evidence suggests that
miRNAs are present in a remarkably stable form in human blood,
where they occur as free circulating nucleic acids, in microvesicles,
and in mononuclear blood cells [7,8]. Recent proof-of-principle
studies demonstrated that the analysis of miRNA expression in
sera or blood cells may be a promising approach for blood-based
diagnosis of a number of human cancers and also autoimmune
diseases [8–10]. Those studies have also shown that global patterns
of miRNA expression might be more revealing than analysis of
single miRNAs. Together, the previous findings suggest that
miRNA expression signatures in blood have the potential to serve
as biomarkers for various human diseases.
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7440Here, we investigated miRNA expression patterns in blood cells
of patients with relapsing-remitting MS (RRMS), as compared to
healthy controls, using a miRNA microarray which contains all
866 human miRNAs and miRNA star sequences deposited in the
Sanger miRBase version 12.0 [http://microrna.sanger.ac.uk/
sequences/, 11]. We thereby identified 165 significantly deregu-
lated miRNAs in MS and demonstrate that unique miRNA
signatures in patients with RRMS allow accurate differentiation
from healthy controls. These data suggest that miRNA expression
signatures may represent a potentially useful biomarker for the
diagnosis of MS and that dysregulation of miRNA expression
could play a role in the complex pathogenesis of MS.
Results
Altered miRNA expression in patients with relapsing-
remitting MS
We analyzed the expression of 866 miRNAs and miRNA star
sequences in blood cells of 20 patients with RRMS as well as 19
healthy controls. Demographic and clinical details of the study
subjects are listed in Supplemental Table S1. Following RNA
isolation and on-chip labeling of miRNAs, the miRNA expression
profiles were measured using the Geniom Biochip miRNA homo
sapiens and the Geniom Real Time Analyzer GRTA (febit
GmbH, Heidelberg). Raw images were analyzed using the
Geniom Wizard software and the intensity values were back-
ground subtracted and quantile normalized. To test the repro-
ducibility of the platform we screened 8 technical replicates of
purchased total RNA (Ambion). We determined a mean
correlation value of 0.97 for the technical replicates. Measurement
of biological replicates showed a mean correlation of 0.87 and a
variance of 0.009.
We next applied hypothesis testing to identify miRNAs
deregulated in blood cells of MS patients as compared to controls.
Following verification of an approximately normal distribution
using Shapiro-Wilk test, we performed two-tailed unpaired t-tests
for each miRNA. The respective p-values were adjusted for
multiple testing by the Benjamini-Hochberg approach. In total, we
detected 165 miRNAs significantly deregulated in blood cells of
MS patients as compared to controls. Histogram plots of the
logarithm of fold quotients, the raw t-test p-values and the adjusted
p-values are presented in Figure 1. A complete list of deregulated
miRNAs is given in Supplemental Table S1. From the 165
significantly deregulated miRNAs 74 (44.8%) were up-regulated
and 91 (55.2%) were down-regulated. The ten miRNAs that were
most significantly deregulated included hsa-miR-145 (1.46?10
27),
hsa-miR-186 (2.89?10
27), hsa-miR-664 (5.25?10
25), hsa-miR-20b
(1.48?10
24), hsa-miR-422a (1.48?10
24), hsa-miR-142-3p
(1.54?10
24), hsa-miR-584 (1.56?10
24), hsa-miR-223 (1.63?10
24),
hsa-miR-1275 (1.16?10
24) and hsa-miR-491-5p (2.83?10
24).
Remarkably, 9 of the best ten miRNA biomarkers (90%) were
significantly up-regulated in MS, while only one miRNA (hsa-
miR-20b) was down-regulated. For the two best miRNAs, hsa-
miR-186 and hsa-miR-145, we present bar plots showing the
intensity values for all MS and control samples in Figures 2a and
2b. For the single down-regulated miRNA hsa-miR-20b, the bar
plot is presented in Figure 2c. Table 1 shows the ten most
deregulated miRNAs. To further validate our data, we performed
RT-qPCR on two miRNAs that are up-regulated in our array
profiles and are associated from literature to be disease related
[12]. In detail, we exemplarily screened 4 diseased and 4 control
samples of miRNAs has-let-7c and has-miR-233. miR-let-7c was
up-regulated 1.57 fold in the arrays of the respective patients and
the RT-qPCR showed a fold change of 1.76. For miR-223, the
Figure 1. Histogram plot of the logarithm of fold changes, raw
t-test p-values and adjusted p-values for all screened miRNAs.
The upper part of the figure shows the logarithms of fold changes.
These are almost normally distributed between -3 and 3. The middle
and bottom part of the figure present histograms of adjusted p-values
for the limma test and t-test. The t-test showed a slightly decreased
number of significant miRNAs. Nevertheless, for both tests a clear
tendency towards low p-values and thus high significance can be seen.
The vertical blue line denotes the significance threshold of 0.05.
doi:10.1371/journal.pone.0007440.g001
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We additionally computed receiver operator characteristic curves
(ROC) for each of the best miRNAs together with the area under
the curve value (AUC). The more the AUC differs from 0.5, the
better a biomarker is. The most extreme values of the AUC are 0
and 1. A value of 1 means, that none of the control values exceeds
any of the MS values. A value of 0 means, that none of the MS
values exceeds any of the control values.
For the best miRNA, hsa-miR-145, we obtained an AUC value
of 0.96. Using this miRNA we classified 35 (89.7%) of the 39
samples correctly, but four samples (9.8%) were misclassified (two
MS sera false negatively, and two control sera false positively)
leading to a specificity of 89.5%, a sensitivity of 90% and an
accuracy of 89.7%. However, these results are not validated by a
re-sampling technique as bootstrapping or cross-validation and are
based only on a single marker.
Evaluating complex fingerprints
In order to improve the statistical reliability we combined the
predictive power of multiple miRNAs by using statistical learning
techniques. In detail, we applied Support Vector Machines (SVM)
with different kernels (linear, polynomial, sigmoid, radial basis
function) to the data and carried out a hypothesis test based on
subset selection as described in Material and Methods. To gain
statistical significance we carried out 100 repetitions of standard
10-fold cross validation. Likewise, we computed 100 repetitions for
the permutation tests where samples with randomly assigned class
labels were classified.
The best results were obtained with radial basis function SVM
and a subset of 48 miRNAs (see Supplemental Table S1). These
miRNAs allowed the discrimination between blood samples of MS
patients and blood samples of controls with an accuracy of 96.3%,
a specificity of 95%, and a sensitivity of 97.6%. The permutation
tests showed significantly decreased accuracy, specificity, and
sensitivity rates, corresponding to random guessing. The classifi-
cation results and the results of the permutation tests are shown in
Figure 3. These results show that the obtained results are not due
to an overfit of the statistical model on the miRNA fingerprints.
Additionally, we present one randomly selected example of a
classification in MS and controls in Figure 4. This graphic shows
for each control (C) and each MS (M) sample the logarithm of the
quotient of the probability to be a MS sample and the probability
to be a control sample. The probabilities have been computed by
the R implementation of the libsvm relying on the distance of the
samples from the separating hyperplane. If the quotient of the
probabilities is greater than one (thus the logarithm is greater zero)
Figure 2. Barplots detailing the intensity values for the miRNAs hsa-miR-145 (a), hsa-mir-186 (b), and hsa-miR-20b (c). MS sera are
indicated by red bars, control sera are indicated by green bars.
doi:10.1371/journal.pone.0007440.g002
Table 1. The ten most significantly deregulated miRNAs.
median MS median normal fold quotient Logarithm of fold quotient t-test adjusted p-values
hsa-miR-145 474,928 150,87 3,148 1,147 1,46E-07
hsa-miR-186 221,159 57,826 3,825 1,341 2,89E-07
hsa-miR-664 563,351 239,837 2,349 0,854 5,25E-05
hsa-miR-20b 2197,846 4746,011 0,463 20,77 0,000148065
hsa-miR-422a 309,874 148,899 2,081 0,733 0,000148065
hsa-miR-142-3p 171,558 21,71 7,902 2,067 0,000154481
hsa-miR-584 266,721 76,725 3,476 1,246 0,000156481
hsa-miR-223 4131,063 1986,446 2,08 0,732 0,00016217
hsa-miR-1275 164,254 92,348 1,779 0,576 0,000163285
hsa-miR-491-5p 192,594 118,522 1,625 0,485 0,000283444
doi:10.1371/journal.pone.0007440.t001
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Figure 4 clearly outlines that in general MS samples have
logarithmized quotients of greater 0 while control samples have
quotients of below 0.
No influence of age, gender, and MS therapy on miRNA
expression profiles
To cross-check that age and gender did not influence our
analysis, we computed t-tests using the normal samples. In case of
males versus females we did not find any statistically significant
deregulated miRNA. The most significant miRNA, hsa-miR-423,
showed an adjusted significance level of 0.78. To test for the
influence of donor age we compared the profiles obtained from old
versus young patients by splitting the total group in half based on
the age. Here, the most significant miRNA, hsa-miR-890,
obtained an adjusted p-value of 0.87. As for gender, we did not
find any deregulated miRNAs, thus providing evidence that age
and gender do not have a substantial influence on the miRNA
profiles. Additionally, we determined the influence of MS therapy
by comparing the group of patients treated with glatiramer acetate
(n=9) to the group treated with interferon-b (n=10). As for
gender and age we did not find any significantly deregulated
miRNAs between those two groups.
MiRNA deregulated in patients with MS only partially
overlap with miRNAs previously associated with other
human diseases
To examine if the detected 165 significantly deregulated
miRNAs are already related to other human diseases we used
the ‘‘Human microRNA Disease Database (HMDD)’’ that
contains information on deregulated miRNA for over 100 human
diseases. Altogether, over 2000 relations are included in the
HMDD [12]. We created a bipartite graph were red nodes
indicate miRNAs and yellow nodes indicate human diseases (see
Figures 5 and 6). Edges between a miRNA and a disease indicate
deregulated miRNAs in the respective disease.
We created a network containing 452 nodes, 137 of which
belong to diseases and 315 to miRNAs. The network, which is
shown in Figure 3 (an enlarged high-resolution poster version is
Figure 3. Boxplot of the classification results. The blue boxes
show the classification accuracy, specificity and sensitivity over the
repeated cross-validation for a subset of 48 miRNAs. The red boxes
show the respective accuracy, specificity and sensitivity for permutation
test.
doi:10.1371/journal.pone.0007440.g003
Figure 4. Exemplarily classification result. The logarithm of the
quotient of the probability to be a MS sample and the probability to be
a control sample for each control (C) and each MS (M) sample is given
on the y-axis. If this quotient is greater than one (thus the logarithm
greater zero) the sample is more likely to be a MS sample than a control
sample.
doi:10.1371/journal.pone.0007440.g004
Figure 5. Complete disease network without MS. The network
indicates human diseases by yellow nodes and miRNAs by red nodes.
An edge between a disease and a miRNA indicates a miRNA that has
previously been associated with the respective disease. This figure is
available as DIN A0 Poster within the Supplemental Material
(Supplemental Figure S1).
doi:10.1371/journal.pone.0007440.g005
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1617 unique edges. Since MS is not included as disease in this
network, we modified the network as follows: We added a disease
node ‘‘Multiple Sclerosis’’ and created edges between this node
and all significant deregulated miRNAs. Additionally, we removed
all disease nodes that are not linked to any MS miRNA and all
miRNAs belonging only to removed disease nodes. Our novel
network, which is shown in Figure 4 thus contains only those
miRNAs that are significant in MS and other diseases (middle part
of Figure 4) and those that are significant in MS, only. This
shrunken network contained 76 disease nodes together with the
165 significant miRNAs. Remarkably, only 43 of the 165 (26%)
miRNAs were related to a disease other than MS while the
remaining 122 (74%) miRNAs were only connected to MS. Of
these 122 miRNAs, 33 (27%) were so-called mature star
sequences. These results provide strong evidence that the detected
complex miRNA profile appears to be rather specific for MS.
Discussion
In this study, we identified 165 significantly deregulated
miRNAs in blood cells of patients with RRMS compared to
healthy controls. The most significant deregulated miRNA, hsa-
miR-145, differentiated between MS patients and healthy controls
with an accuracy, specificity, and sensitivity of 89.7%, 89.5%, and
90.0%, respectively. Using a set of 48 of the 165 significantly
deregulated miRNAs, we were able to improve the classification
results, reaching an accuracy of 96.3%, a specificity of 95%, and a
sensitivity of 97.6%. Together, these data suggest that single
miRNAs, and even more so miRNA expression profiles, may have
the potential to serve as diagnostic biomarkers for RRMS.
Since our study includes patients with MS and healthy controls
only, future investigations should corroborate the specificity of the
observed miRNA expression patterns for MS by including groups
of patients with other inflammatory neurological diseases.
Comparison of the pattern of deregulated MS miRNAs with
miRNAs previously found to be deregulated in other human
diseases showed a remarkably high percentage of miRNAs (74%)
that are deregulated in MS but not in any other disease. Notably,
these diseases comprise neoplastic and degenerative neurological
diseases as well as systemic inflammatory diseases (see Figures 5
and 6). However, prior to claiming specificity it is necessary to test
the expression of each miRNA on an extended number of MS
patients and controls by at least two independent methods.
Currently, only one additional study investigated miRNA
expression in patients with MS [3]. Otaegui and coworkers
analyzed four patients with MS during a relapse and nine MS
patients during remission. Patients during relapse and patients
during remission were compared with each other and with eight
healthy individuals using a non-parametric ranking method called
Symmetrical Uncertainty (SU). In total Otaegui et al. analyzed the
expression of 364 miRNAs in peripheral mononuclear cells
(PBMC). In our study, we analyzed all 866 miRNAs and miRNA
star sequences deposited in the miRBase version 12.0 and ranked
the miRNAs according to their AUC value for the classification
MS versus healthy. Comparing the results of Otaegiu et al. with
our results, we found an overlap of seven miRNAs which had high
information content in both studies. Of these seven miRNAs, the
four miRNAs hsa-miR-509-3-5p, hsa-miR-214, hsa-miR-34c-3p,
and hsa-miR-509-5p show an AUC value lower than 0.3 in our
study, indicating a higher expression in healthy individuals
compared to MS patients. The remaining three miRNAs, namely
hsa-miR-328, hsa-miR-30a, and hsa-miR-30e, showed higher
expression in the blood cells of MS patients compared to the blood
cells of healthy individuals, as indicated by AUC values higher
than 0.7.
The small number of miRNAs that are highly informative in
both studies may be due to the different experimental approaches
used in the two studies. While Otaegui et al. performed
quantitative Real Time-PCR we hybridized microarrays with
labeled RNA without an initial reverse transcription or amplifi-
cation step. In addition, our study analyzed more than twice as
many miRNAs than the study of Otaegui and colleagues.
Besides the potential role of miRNAs as biomarkers for RRMS,
the finding of deregulated miRNA expression in patients
with MS suggests that the disease process of MS may result
in altered miRNA expression profiles or that deregulation of
miRNAs may contribute to the disease process of MS. Among the
ten most deregulated miRNAs, hsa-miR-145, hsa-miR-186, and
hsa-miR-20b have been found to be deregulated in different types
of cancer such as prostate cancer, pancreatic cancer or gastric
Figure 6. Multiple Sclerosis Network. This network indicates diseases by yellow nodes and miRNAs by red nodes. The network is restricted to the
miRNAs significant for MS. Most of the miRNAs are associated with MS but not with other diseases, indicated by the red circles in the right part of this
figure. This figure is available as DIN A0 Poster within the Supplemental Material (Supplemental Figure S2).
doi:10.1371/journal.pone.0007440.g006
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deregulated miRNAs in our study, namely hsa-miR-142-3p
and hsa-miR-223, have previously been found to be differentially
expressed in hematopoietic cell lineages. hsa-miR-142-3p is
also highly expressed in T-cells [16,17]. This may be compatible
with a role of these miRNAs in haematopoiesis and probably
in the immune system. Five out of the ten most deregulated
miRNAs (miRNAs hsa-miR-664, hsa-miR-422a, hsa-miR-584,
hsa-miR-1275, and hsa-miR-491-5p) have not yet been associated
with any specific functions or human diseases.
In conclusion, the data presented in this study demonstrate that
miRNA expression profiles differentiate patients with MS from
healthy subjects with high accuracy, indicating that miRNAs have
the potential to serve as a diagnostic biomarker for RRMS. Future
studies should clarify whether these small molecules are also suited
for differentiation of specific courses or different pathogenetic
subtypes of MS.
Materials and Methods
Patients with MS and healthy controls
We included 20 patients with a diagnosis of RRMS according to
McDonald criteria [18] as well as 19 healthy controls in our study
(see supplemental Table S1). Patients were either treated with
glatiramer acetate (n=9), or interferon-b (n=10), or did not take
any disease-modifying therapy (n=1). None of the patients had
received glucocorticosteroids for at least 3 months before inclusion
in the study. All participants of the study have given their written
informed consent. Blood from MS patients was obtained during
clinical diagnosis. Blood analysis from healthy donors was also
performed with written informed consent.
miRNA microarray screening
About 5 ml blood was collected from study subjects in PAXgene
Blood RNA tubes (BD, Franklin Lakes, New Jersey USA). Total
RNA was extracted from blood cells using the miRNeasy Mini Kit
(Qiagen GmbH, Hilden, Germany) and stored at 270uC. Samples
were analyzed with a Geniom Realtime Analyzer (GRTA, febit
GmbH, Heidelberg, Germany) using the Geniom Biochip miRNA
homo sapiens. Each array contains 7 replicates of 866 miRNAs
and miRNA star sequences as annotated in the Sanger miRBase
12.0 [11]. Sample labelling with biotine was carried out by
microfluidic-based enzymatic on-chip labelling of miRNAs
(MPEA) as described before [19].
Following hybridization for 16 hours at 42uC the biochip was
washed automatically and a program for signal enhancement was
processed with the GRTA. The resulting detection pictures were
evaluated using the Geniom Wizard Software. For each array, the
median signal intensity was extracted from the raw data file such
that for each miRNA seven intensity values were calculated
corresponding to each replicate copy of miRBase on the array.
Following background correction, the seven replicate intensity
values of each miRNA were summarized by their median value.
To normalize the data across different arrays, quantile normal-
ization was applied and all further analyses were carried out using
the normalized and background subtracted intensity values.
The raw data and normalized data are available under Gene
Expression Omnibus, one of the largest MIAME compatible
expression profile resources on the web, under accession
GSE17846.
Statistical analysis
After having verified the approximate normal distribution of the
measured data using Shapiro Wilk test, we carried out parametric
t-test (unpaired, two-tailed) for each miRNA separately, to detect
miRNAs with different expression levels between study groups.
The resulting p-values were adjusted for multiple testing by
Benjamini-Hochberg adjustment.
To analyze the relationship of the detected miRNAs to miRNAs
previously detected in other human diseases we used the ‘‘Human
miRNA-associated Disease Database (HMDD, [12], http://202.
38.126.151/hmdd/login/?next=/hmdd/mirna/md/). In more
detail, we built a bipartite graph where nodes correspond either
to a miRNA or to a disease. Only edges between miRNA and
disease nodes are allowed, where an edge between miRNA A and
disease B means that the miRNA A is differentially regulated in
disease B. Since for MS no deregulated miRNAs have been
described so far we added the node ‘‘Multiple Sclerosis’’ to this
network and linked it to all miRNAs that were significant
deregulated in our analysis.
In addition to the single biomarker analysis and network analysis,
classification of samples using miRNA patterns was carried out
using Support Vector Machines (SVM) as implemented in the R
e1071 package. In particular, different kernel (linear, polynomial,
sigmoid, radial basis function) SVMs were evaluated, where the cost
parameter was sampled from 0.01 to 10 in decimal powers. The
measured miRNA profiles were classified using 100 repetitions of
standard 10-fold cross-validation.
To detect the most suitable set of miRNAs that achieves the best
discriminatory performance, a feature extraction (subset selection)
method relying on t-test p-values has been used. In detail, we
decided to use the following stepwise forward filter approach: The
s miRNAs with lowest p-values in the t-test were computed on the
training set in each fold of the cross validation, where s was
sampled from 1 to 866. The respective subset was used to train the
SVM and to carry out the prediction of the test samples. As result,
the mean accuracy, specificity, and sensitivity were calculated
together with the 95% confidence intervals (95% CI) for each
subset size. To check for overtraining we applied permutation
tests. Here, we sampled the class labels randomly and carried out
classifications using the permuted class labels. All statistical
analyzes were performed using R.
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